Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.50 |
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487194 | 1.00 | CSNK2A1 (0.50) | CSNK2A1PNMTTAAR1LOXL2PIK3CA | |
| SCHEMBL793707 | 0.84 | TAAR1 (0.69) | PNMTTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL3271461 | 0.83 | TAAR1 (0.67) | PNMTTAAR1SLC6A3 | |
| SCHEMBL295912 | 0.82 | PNMT (0.48) | CSNK2A1PNMTTAAR1LOXL2SLC6A3 | |
| SCHEMBL20019811 | 0.81 | TAAR1 (0.53) | PNMTTAAR1PIK3CASLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5958057 | 0.80 | CSNK2A1 (0.47) | CSNK2A1PNMTTAAR1LOXL2SLC6A3 | |
| Hydrochloric Acid SCHEMBL15518193 | 0.79 | TAAR1 (0.52) | PNMTTAAR1PIK3CASLC6A4SLC6A3 | |
| SCHEMBL923443 | 0.79 | ST14 (0.58) | LOXL2SLC6A4 | |
| SCHEMBL16388285 | 0.79 | PIK3CA (0.45) | PNMTTAAR1PIK3CASLC6A4SLC6A3 | |
| SCHEMBL1503218 | 0.79 | PIK3CA (0.45) | PNMTTAAR1PIK3CASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| CN-117510429-A | Compound containing methyl isoxazole structure, and preparation method and application thereof | 中国农业大学 | 2024-02-06 | — | — | CN | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | claimed |
| CN-102911124-A | Hydroxy-pyrimidone compound and preparation method and application thereof | UNIV SHANDONG | 2013-02-06 | — | — | CN | claimed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | claimed |
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| US-12516039-B2 | N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250345293-A1 | Plasminogen Activator Inhibitor-1 (PAI-1) Inhibitor and Method of Use | UNIV MICHIGAN REGENTS (US) | 2025-11-13 | — | — | US | disclosed |
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | KUKJE PHARMA CO., LTD. (KR) | 2025-11-11 | — | — | US | disclosed |
| US-12390427-B2 | Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use | EASTERN MICHIGAN UNIVERSITY (US) | 2025-08-19 | — | — | US | disclosed |
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2025-06-03 | — | — | US | disclosed |
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
| US-5780505-A | ADMINISTERING AS SMOOTH MUSCLE RELAXANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| CN-1184423-A | Nodulisporic acid derivatives | MERCK & CO INC (US) | 1998-06-10 | — | — | CN | disclosed |
| WO-1998002413-A1 | SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| EP-0819000-A1 | NODULISPORIC ACID DERIVATIVES | Merck & Co., Inc. (US) | 1998-01-21 | — | — | EP | disclosed |
| EP-0746558-A1 | PHENYLALKYLAMINO DERIVATIVES OF CONDENSED CARBAPENEMES | GLAXO WELLCOME S.p.A. (IT) | 1996-12-11 | — | — | EP | disclosed |
| WO-1996029073-A1 | NODULISPORIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1996-09-26 | — | — | WO | disclosed |
| WO-1995023149-A1 | PHENYLALKYLAMINO DERIVATIVES OF CONDENSED CARBAPENEMES | GLAXO WELLCOME S.P.A. (IT) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | PTGES, PTGES2, PTGS1 | CSNK2A1 257/4885PNMT 829/4885TAAR1 786/4885 |
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR6, HTR2C | CSNK2A1 2990/4885PNMT 25/4885TAAR1 56/4885 |
| US-12390427-B2 | Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use | SERPINE1, PLAT, SERPINC1 | CSNK2A1 4574/4885PNMT 1733/4885TAAR1 3601/4885 |
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | MRGPRX2, MRGPRX1, MRGPRX4 | CSNK2A1 2528/4885PNMT 3178/4885TAAR1 168/4885 |
| US-20250345293-A1 | Plasminogen Activator Inhibitor-1 (PAI-1) Inhibitor and Method of Use | SERPINE1, PLAT, SERPINC1 | CSNK2A1 4574/4885PNMT 1733/4885TAAR1 3601/4885 |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | CSNK2A1 2519/4885PNMT 823/4885TAAR1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.